FDA Approves Natera's Signatera Bladder Cancer Test After Strong Trial Results
NTRA sits 41% above its 52-week low of $131.811.
Summary
Natera has secured FDA approval for its Signatera CDx test for bladder cancer, marking a significant regulatory win. The test is approved as a companion diagnostic for adjuvant atezolizumab in treating muscle-invasive bladder cancer. This approval follows trial data demonstrating significant improvements in disease-free and overall survival for patients who tested positive with Signatera and received immunotherapy. This development opens a new and material market opportunity for Natera in oncology diagnostics, expanding its product portfolio and revenue potential beyond its existing offerings. Traders will now focus on the company's commercialization strategy and the test's anticipated revenue contribution.
At the time of this announcement, NTRA was trading at $186.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.7B. The 52-week trading range was $131.81 to $256.36. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.